95 related articles for article (PubMed ID: 17896601)
1. Manipulating T regulatory cells for cure of ulcerative colitis: ground zero in crosshairs.
Ahuja V
Trop Gastroenterol; 2007; 28(1):1-3. PubMed ID: 17896601
[No Abstract] [Full Text] [Related]
2. [Destabilization of the immune homeostasis in patients with nonspecific ulcerative colitis of varying degrees of severity].
Burmistrova AL
Ter Arkh; 1992; 64(2):83-6. PubMed ID: 1509393
[TBL] [Abstract][Full Text] [Related]
3. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of ulcerative colitis.
Dalal L
J Assoc Physicians India; 2007 Sep; 55():635-40. PubMed ID: 18051737
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics of the disorders of the T chain of the immune system in nonspecific ulcerative colitis and their significance in choosing effective therapy].
Shakhnazarov AA
Ter Arkh; 1984; 56(2):106-8. PubMed ID: 6608803
[No Abstract] [Full Text] [Related]
6. [Immuneprophylaxis of purulent and septic complications with Derinat at surgical treatment of calculous cholecystitis].
Zubeev PS; Strakhov AV; Maksimychev VN; Motylev IM
Khirurgiia (Mosk); 2007; (5):56-9. PubMed ID: 17690682
[No Abstract] [Full Text] [Related]
7. [Changes in the indices of cellular and humoral immunity in patients with gastrointestinal ulcer].
Perederiĭ VG; Shakhnazarov AA
Vrach Delo; 1983 Aug; (8):83-5. PubMed ID: 6605623
[No Abstract] [Full Text] [Related]
8. Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis.
Nakamura T; Nagahori M; Kanai T; Watanabe M
Digestion; 2008; 77 Suppl 1():36-41. PubMed ID: 18204260
[TBL] [Abstract][Full Text] [Related]
9. Loss of T-bet sends host-microbe mutualism awry.
Ma A
Cell; 2007 Oct; 131(1):15-7. PubMed ID: 17923080
[TBL] [Abstract][Full Text] [Related]
10. [The bacteriological and immunological efficacy of biosporin in nonspecific ulcerative colitis].
Cherniakova VI; Bereza NM; Selezneva SI; Chaplinskiĭ VIa; Kudriavtseva VE; Mosalova NM; Shevtsova ZI; Tropko LV; Boĭko TI
Mikrobiol Zh (1978); 1993; 55(3):63-7. PubMed ID: 8355632
[TBL] [Abstract][Full Text] [Related]
11. [Indicators of immunity in nonspecific ulcerative colitis after drainage of the thoracic duct].
Kharaberiush VA; Kvasha VI; Siniachenko OV; Nikolenko IuI
Klin Med (Mosk); 1981 Feb; 59(2):41-4. PubMed ID: 6974801
[No Abstract] [Full Text] [Related]
12. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis.
Boirivant M; Amendola A; Butera A; Sanchez M; Xu L; Marinaro M; Kitani A; Di Giacinto C; Strober W; Fuss IJ
Gastroenterology; 2008 Nov; 135(5):1612-1623.e5. PubMed ID: 18765239
[TBL] [Abstract][Full Text] [Related]
13. Preparation of functionally preserved CD4+ CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy.
Sumida Y; Nakamura K; Kanayama K; Akiho H; Teshima T; Takayanagi R
Cytotherapy; 2008; 10(7):698-710. PubMed ID: 18985477
[TBL] [Abstract][Full Text] [Related]
14. The role of endoscopic assessment in ulcerative colitis in the era of infliximab.
Daperno M; Sostegni R; Pera A; Rognone D; Rigazio C; Ercole E; Crocellà L; Lavagna A; Rocca R
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S220-4. PubMed ID: 18598992
[TBL] [Abstract][Full Text] [Related]
15. Clinical practice in the management of ulcerative colitis--an Italian survey.
Fries W; Costa S; Costantino G; Familiari L
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S214-9. PubMed ID: 18598991
[TBL] [Abstract][Full Text] [Related]
16. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways.
Yu QT; Saruta M; Papadakis KA
Clin Immunol; 2008 Jun; 127(3):322-9. PubMed ID: 18424236
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of typical immune reactions in myocardial infarction].
Zemskov AM; Alekhina OD; Zemskov VM; Zemskov MA; Zoloedov VI
Ter Arkh; 2008; 80(1):32-7. PubMed ID: 18326224
[TBL] [Abstract][Full Text] [Related]
19. Worm therapy for ulcerative colitis: a possible link to regulatory T cells.
Yuan Q; Walker WA
J Pediatr Gastroenterol Nutr; 2005 Jul; 41(1):139-40. PubMed ID: 15990650
[No Abstract] [Full Text] [Related]
20. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
